Lowering Intracranial Pressure in Idiopathic Intracranial Hypertension: Assessing the Therapeutic Efficacy and Safety of an 11β-hydroxysteroid Dehydrogenase Type 1 Inhibitor (AZD4017). Phase II Study.

Trial Profile

Lowering Intracranial Pressure in Idiopathic Intracranial Hypertension: Assessing the Therapeutic Efficacy and Safety of an 11β-hydroxysteroid Dehydrogenase Type 1 Inhibitor (AZD4017). Phase II Study.

Completed
Phase of Trial: Phase II

Latest Information Update: 10 May 2017

At a glance

  • Drugs AZD 4017 (Primary)
  • Indications Pseudotumour cerebri
  • Focus Therapeutic Use
  • Acronyms IIH:DT
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 29 Mar 2017 Status changed from active, no longer recruiting to completed.
    • 25 Oct 2016 Planned End Date changed from 1 Aug 2016 to 1 Dec 2016.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top